Armata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has agreed to an Agreed Initial Pediatric Study Plan (Agreed iPSP) for the evaluation of AP-SA02 for treating complicated Staphylococcus aureus bacteremia (SAB) in pediatric patients. Armata Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutic solutions for infectious diseases.
